Monitoring the cytokine storm in severe cases of COVID-19 disease
Rapid and accurate profiling of biomarker signatures in clinical samples is increasingly important to monitoring therapeutic interventions. Such an approach may prove relevant for COVID-19 as well. Several studies provide preliminary evidence that cytokine release syndrome (CRS) – also called “cytokine storm” – may play a role in severe cases of the new disease (1, 2). Such cases exhibit acute respiratory distress syndrome (ARDS), which can be triggered by a cascade of hyperinflammatory events and excessive cytokine release leading eventually to multi-organ failure and death.
The LUNARIS™ platform enables monitoring of the “cytokine storm”. Clinical samples (e.g., serum, plasma, saliva etc.) as small as 3 µL in volume can be simultaneously analyzed to quantify up to 12 biomarkers (or more) with high precision and sensitivity in simple workflow for up to 384 samples.
- Identify biomarker signatures associated with severe COVID-19
- Elucidate disease mechanisms and find potential therapy targets
- Uncover molecular signals that can help guide treatment options
AYOXXA has been working with global leaders in clinical research (3) to better understand CRS in the context of several diseases and therapeutic interventions. Our know-how, expertise and tools can open new avenues to contain SARS-CoV-2 and possibly save lives as COVID-19 cases continue to rise over the coming months.
Let us know how we can advance your COVID-19 research!
1 Mehta et al., Lancet. 2020 Mar 16, pii: S0140-6736(20)30628-0.
2 Huang et al., Lancet. 2020 Feb 15; 395(10223):497-506.
3 Karantanos et al., Bone Marrow Transplant. 2019 Oct 2; doi: 10.1038/s41409-019-0707-x.
About AYOXXA
AYOXXA Biosystems is dedicated to the vision of enabling success in translational research. Building upon an innovative technology platform, our mission is to develop robust assay panels for translational research applications. Our LUNARIS™ multiplex protein analysis platform is optimized for translating knowledge from basic to clinical research. With its advantages in terms of quality, flexibility and efficiency, LUNARIS™ enables reliable quantification of biomarkers from model to man – from lab to clinic – from data to insight.
Contact:
AYOXXA Biosystems GmbH
Dr. Matthias Jansen (Global Marketing Manager)
BioCampus Cologne
Nattermannallee 1 | 50829 Köln | Germany
phone: +49 (0) 221 – 222 529– 0
fax: +49 (0) 221 – 222 529– 11
e-mail: